Clinical trials have demonstrated that a long-term treatment with carvedilol,a new adrenoreceptor blocker,non-selectively antagonized β1、β2 and α1-receptor,can decrease the mortality of patients with congestive heart failure.This article reviews the effects of carvedilol in congestive heart failure.